What is Moderna?
mRNA medicines and vaccines company with $1.944B 2025 revenue scale and public-market buying capacity.
- Category
- mRNA medicines and vaccines
- Headquarters
- Cambridge, MA
- Founded
- 2010
- Employees
- 5,600+
- Total funding
- Public company; no VC funding
- Status
- Nasdaq: MRNA; Public company
What is Moderna?
Moderna is a public mrna medicines and vaccines company headquartered in Cambridge, MA. Moderna's annual revenue for 2025 was approximately $1.944 billion, and Q1 2026 revenue was $389 million as respiratory-vaccine demand remained seasonal.
Moderna operates in mrna medicines and vaccines with a portfolio that includes Spikevax, mRESVIA, Seasonal flu pipeline, COVID/flu combination pipeline. Moderna's annual revenue for 2025 was approximately $1.944 billion, and Q1 2026 revenue was $389 million as respiratory-vaccine demand remained seasonal. The company employs about 5,600+ and trades as Nasdaq: MRNA, so its buying motion looks like a regulated enterprise account rather than a startup account.
Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Moderna through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.
For sellers, Moderna is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.
What does Moderna offer?
Moderna offers products and services across Spikevax, mRESVIA, Seasonal flu pipeline, COVID/flu combination pipeline and related healthcare workflows.
- Spikevax· COVID-19 vaccine
- mRESVIA· RSV vaccine
- Seasonal flu pipeline· Respiratory vaccines
- COVID/flu combination pipeline· Respiratory vaccines
- Individualized neoantigen therapy· Oncology
- Rare disease mRNA programs· Therapeutics
How does Moderna make money?
Moderna earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.
Moderna earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $1.944B 2025 of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.
Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.
Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Moderna improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.
Who leads Moderna?
Moderna is led by Stephane Bancel, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.
- Stephane BancelChief Executive OfficerCEO since 2011Leads Moderna's mRNA platform, cost reset, and respiratory-vaccine commercialization.
- Stephen HogePresidentPresident since 2020Oversees platform strategy, medical, and development priorities.
- Jamey MockChief Financial OfficerCFO since 2022Runs finance, cost discipline, and capital allocation.
- Francesca CeddiaChief Medical Affairs OfficerMedical leader in 2026Guides medical affairs and evidence strategy.
How do you contact Moderna's leadership?
Moderna publishes official Moderna investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.
official Moderna investor-relations contact route; personal executive email format not verifiedHow much funding has Moderna raised?
Moderna is a mature public company, not a venture-backed startup. It trades as Nasdaq: MRNA and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.
Moderna's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.
As of June 2026, the current capital lens is Nasdaq: MRNA, $1.944B 2025 of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.
Seller signal: Moderna has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.
How did Moderna get here?
Moderna grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.
- 2010Moderna foundedThe company begins developing mRNA as a medicines platform.
- 2018IPOModerna completes one of the largest biotech IPOs at the time.
- 2020COVID-19 vaccine authorizationSpikevax brings Moderna to global commercial scale.
- 2024RSV vaccine approvedmRESVIA expands the marketed respiratory-vaccine portfolio.
- 2025$1.944B revenueRevenue resets from pandemic peak levels as respiratory demand normalizes.
- 2026Q1 revenue improvesModerna reports Q1 2026 revenue of $389 million.
Who are Moderna's competitors?
Moderna competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.
- BioNTechCompetes in mRNA vaccines, oncology immunotherapy, and platform partnerships.
- PfizerCompetes in COVID-19, RSV, vaccines, and global commercial access.
- NovavaxCompetes in COVID-19 and respiratory vaccines.
- GSKCompetes in RSV, flu, and broad vaccine portfolios.
- SanofiCompetes in vaccines, immunology, and global public-health markets.
- BioNTechmRNA immunotherapy and vaccine company competing for infectious disease and oncology platform programs.
Moderna — frequently asked questions
